Cancer Diagnostic Testing World Markets - Hawaii News Now - KGMB and KHNL

Cancer Diagnostic Testing World Markets

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE ReportBuyer

LONDON, June 11, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Cancer Diagnostic Testing World Markets

http://www.reportbuyer.com/pharma_healthcare/diagnostics/cancer_diagnostic_testing_world_markets.html

Cancer testing is one of the most important growth opportunities for the next three to five years in the diagnostics segment. The National Cancer Institute estimates that about ten million Americans have or have had some form of cancer. Overall costs of the disease are $126 billion annually. Pharmaceutical companies are developing more than 300 new medicines for cancer, some of which are in development for more than one type of the disease, for a total of more than 500 ongoing R&D projects. The goal of this TriMark Publications report is to review the market for tumor marker testing equipment and supplies using screening reagents and instruments for analysis of individual components in blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including: the physician office labs, hospital labs and commercial laboratories. Additionally, the numbers of institutions using this type of testing and the factors that influence purchases are discussed. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the clinical point-of-care market in the U.S. Each company is discussed in depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position.

TABLE OF CONTENTS

1. Overview 9
1.1 Statement of Report 9
1.2 About this Report 9
1.3 Scope of the Report 11
1.4 Objectives 11
1.5 Methodology 11
1.6 Executive Summary 13

2. Introduction to Cancer Biology and the Diagnostic Industry 18
2.1 Cancer 18
2.1.1 The Disease 18
2.1.2 Metastasis 19
2.1.3 Demographics and Statistics of Cancer 19
2.2 The Drivers of the Biotech and Diagnostics Industry 24
2.2.1 Technological Innovation 26
2.2.2 Government Funding 26
2.3 Outlook for Tumor Markers 26

3. Tumor Markers Market Segment Analysis: Size, Growth and Share 29
3.1 Market Description 30
3.2 Clinical Diagnostic Serum-based Cancer Markers 37
3.3 PSA Testing Market Size 38
3.4 DNA Markers 39
3.5 Serum Proteins 39
3.6 Enzymes 40
3.7 Occult Blood 40
3.8 Histology and In Situ Hybridization (ISH) 41
3.9 Cervical Cytology 41
3.10 Immunohistochemistry (IHC) 44
3.11 In Vivo Detection Cancer Products 45
3.12 Radionuclides and X-Ray Detection Products 45
3.13 HPV Testing 45
3.14 Bladder Cancer Testing 48
3.15 Tumor Assays for Adjuvant Chemotherapy 52

4. Diagnostic Methods for Cancer Detection 66
4.1 Organ-Specific Tumor Markers 66
4.1.1 Colon Cancer 66
4.1.2 Prostate Cancer 77
4.1.3 Pancreatic Cancer 114
4.1.4 Breast Cancer 119
4.1.5 Ovarian Cancer 132
4.1.6 Cervical Cancer 138
4.1.7 Lung Cancer 145
4.1.8 Testicular Cancer 155
4.1.9 Bladder Cancer 155
4.1.10 Hepatic Cancer 164
4.1.11 Stomach Cancer 167
4.1.12 Malignant Melanoma 168
4.1.13 Acute Myeloid Leukemia (AML) and Acute Lymphoblastoid Leukemia (ALL) 169
4.1.14 Lymphoma 170
4.2 Clinical Laboratory Methods for Measuring Tumor Markers 170
4.2.1 Abbott Diagnostics AxSYM 170
4.2.2 Roche Diagnostics Systems 171
4.2.3 Beckman Coulter Diagnostics Immunoassay Systems 172
4.2.4 Siemens Healthcare Diagnostics ADVIA Centaur CP Immunoassay System and the
ADVIA Centaur XP Immunoassay System 173
4.2.5 Siemens Healthcare Diagnostics Immulite Systems 173
4.2.6 Tosoh Bioscience AIA-2000 174
4.2.7 Thermo Fisher Scientific B.R.A.H.M.S. KRYPTOR 175
4.2.8 Ortho-Clinical Diagnostics Vitros ECiQ (Johnson and Johnson) 175
4.2.9 Fujirebio Diagnostics, Inc. 175
4.2.10 bioMérieux Vidas 176
4.3 New Technologies for Cancer Diagnostics 177
4.3.1 New and Improved Immunoassays 177
4.3.2 IHC Tests 178
4.3.3 Molecular (DNA and Genomic) Diagnostic Assays 179
4.3.4 Genomics and Genetic Markers 179
4.3.5 Proteomics and New Protein Markers 180
4.3.5.1 Inside the ProteinChip System 181
4.3.5.2 Rapid Biological Assays on a Chip 181
4.3.5.3 Proteome Pattern Recognition 181
4.3.6 New Platform Technologies Including Flow Cytometry 182
4.3.7 Stem Cell Markers 185
4.3.8 mAbs 186
4.3.9 Proteomics and Cancer Antibodies 187
4.3.10 Pharmacogenomics and Oncology Diagnostics 187
4.3.11 DNA Microarrays 190
4.3.12 In Vitro Diagnostic Multi-variate Index Assays (IVDMIA) 192
4.3.13 Prostate PX Score 192
4.3.14 Prostate-63 192
4.3.15 Future Directions 192
4.4 Clinical Methods for Diagnosis of Cancer 193
4.4.1 Screening 193
4.4.2 Sigmoidoscopy 195
4.4.3 Imaging 195
4.4.4 Theranostics 197

5. Implications of Molecular Biology for New Diagnostic Cancer Tests 198

6. Companies Entering the Cancer Diagnostics Market with Novel Technology
Platforms 200
6.1 Abbott Diagnostics 200
6.2 Affymetrix, Inc. 201
6.3 Agendia BV 202
6.4 Ambrilia Biopharma, Inc. 202
6.5 ArcticDx, Inc. 203
6.6 Arcxis Biotechnologies 203
6.7 Asuragen, Inc. 204
6.8 Aureon Biosciences, Inc. 204
6.9 C. R. Bard 204
6.10 Beckman, Dickinson and Company (BD) Diagnostics-TriPath 205
6.11 Beckman Coulter (now part of Danaher Corporation) 206
6.12 Biocode Hycel France S.A. 208
6.13 BioCurex 209
6.14 Biomedical Diagnostics 209
6.15 Biomerica 209
6.16 bioMérieux 210
6.17 BioModa, Inc. 210
6.18 Bruker Daltonics 211
6.19 Byk Gulden 211
6.20 Cepheid 211
6.21 Clarient, Inc. (GE Healthcare) 213
6.22 CombiMatrix Corporation 213
6.23 Correlogic Systems, Inc. (Vermillion, Inc.) 214
6.24 CytoCore (formerly Molecular Diagnostics, Inc.) 214
6.25 Cytogen Corporation (now EUSA Pharma) 214
6.26 diaDexus, Inc. 215
6.27 DiagnoCure, Inc. 216
6.28 Diagnostic Automation/Cortez Diagnostics, Inc. 217
6.29 DRG International, Inc. 217
6.30 Eisai Co., Ltd. 218
6.31 Enigma Diagnostics Ltd. 219
6.32 Epigenomics AG 219
6.33 Exact Sciences Corporation 219
6.34 Exagen Diagnostics, Inc. 220
6.35 Exiqon 221
6.36 Fujirebio Diagnostics, Inc. 221
6.37 Gene Logic, Inc. 222
6.38 Gen-Probe, Inc. 222
6.39 Genomic Health, Inc. 222
6.40 Geron Corporation 223
6.41 Hologic, Inc. (formerly Cytyc Corporation) 224
6.42 Immunicon Corporation (now Veridex, LLC) 228
6.43 Immunomedics, Inc. 228
6.44 Ipsogen 229
6.45 LabCorp 229
6.46 Urocor, Inc. 230
6.47 Mitsubishi Kagaku Medical 231
6.48 Molecular Devices (formerly Arcturus Bioscience, Inc.) 231
6.49 Myriad Genetics, Inc. 231
6.50 Northwest Biotherapeutics, Inc. 237
6.51 ARCA Biopharma 238
6.52 Oncotech, Inc. 238
6.53 Oncothyreon, Inc. (formerly Biomira) 238
6.54 Panacea Pharmaceuticals, Inc. 239
6.55 Poniard Pharmaceuticals, Inc. 239
6.56 Polymedco, Inc. 241
6.57 Princeton BioMeditech Corporation 242
6.58 QIAGEN NV 243
6.59 Radient Pharmaceuticals 244
6.60 Roche (F. Hoffman-La Roche Ltd.) 245
6.61 Sanko Junyaku Co., Ltd. 246
6.62 Siemens Heathcare Diagnostics 246
6.63 Seegene 247
6.64 Sequenom, Inc. 248
6.65 SABiosciences Corporation (Qiagen) 248
6.66 Source MDx 248
6.67 Targeted Molecular Diagnostics 248
6.68 Tosoh Corporation (Bioscience division) 249
6.69 Ventana Medical Systems, Inc. 249
6.70 Veridex, LLC 249
6.71 Vermillion, Inc. 249
6.72 Worldwide Medical Corporation 250
6.73 Xenomics, Inc. (TrovaGene, Inc.) 250

7. Business Trends in the Industry 251
7.1 Industry Consolidation 251
7.2 Breadth of Product Offering and Pricing 251
7.3 Government Regulation of Medical Devices 252
7.4 Commercial Opportunities in Cancer Markers 253
7.5 Moderators of Growth 254
7.6 Biotechnology Industry Trends 255
7.7 Pharmaceutical Industry Trends 256
7.8 Sales and Marketing Strategies for Tumor Marker Tests 259
7.8.1 North American Market 260
7.8.2 International Markets 261
7.8.2.1 Europe 261
7.8.2.2 Central and South America 261
7.8.2.3 Asia-Pacific 262

8. Tumor Marker Testing: Important Issues 263
8.1 Trends in Patient Care and Reimbursement 263
8.2 Trends in Reimbursement Practice 264
8.3 Clinical Laboratory Improvement Act (CLIA) 267
8.4 Unmet Needs in Tumor Markers 268

9. Important New Technology Areas 269
9.1 Proteins 269
9.2 DNA Sequencing 270
9.3 The Human Genome Project (HGP) 271
9.4 Liquid Phase Chromatography 272
9.5 Polymerase Chain Reaction (PCR) 273
9.6 Capillary Electrophoresis 274
9.7 Proteomics 275
9.8 Use of Mass Spectrometry (MS) in Sequencing 276
9.9 High-Throughput Organic Synthesis 281

10. New Cancer Markers in Basic Research 282
10.1 Genetics of Cancer 282
10.1.1 Activator Genes (Oncogenes) 282
10.1.2 Inactivating Genes (Tumor Suppressor Genes) 284
10.2 DNA Mismatch Repair Genes (MMRs) 286
10.3 Telomeres 287
10.4 Diseases 291
10.4.1 t(15;17) in Acute Promyelocytic Leukemia (APL) 291
10.4.2 t(12;21) in Acute Lymphoblastic Leukemia (ALL) 291
10.4.3 Retinoblastoma and Constitutional 13q14 Deletion 291
10.4.4 Stomach Cancer 291
10.4.5 Head and Neck Cancer 292
10.4.6 Breast and Ovarian Cancers 293
10.4.7 Prostate Cancer 294
10.4.8 Cervical Cancer: NMPI79 296
10.4.9 Uterine and Kidney Cancer: MN/CA9 296
10.4.10 Colon Cancer: Serum Vascular Endothelial Growth factor (VEGF) 297
10.4.11 Lung Cancer: Ribonucleoprotein A2/B1 and microRNA Markers 297
10.5 Tumor Markers 297
10.5.1 Oncology Biomarker Qualification Initiative 297
10.5.2 CRC: Carcinoembryonic Antigen (CEA) Doubling Time 298
10.5.3 MUC1, 2, 3 and 4 298
10.5.4 Cytokeratins 299
10.5.5 RAK Antigens 299
10.5.6 Serum Urokinase Receptors 299
10.5.7 Survivin 299
10.5.8 Reg-4 Protein 300
10.5.9 NADPH Oxidases 1 and 2 (NOX1 and NOX2) 300
10.5.10 Prostate Secretory Protein 94- (PSP94)-Binding Protein 300
10.5.11 Shc Proteins 301
10.5.12 Anti-Glycan Antibodies 301
10.5.13 YKL-40 301
10.5.14 Alpha-Fetoprotein (AFP)-L3 302
10.5.15 Transthyretin and Apo Lipoprotein A1 (Apo A1) 302
10.5.16 A Disintegrin and Metalloproteinase (ADAM) 302
10.6 Technology 302
10.6.1 Chips 302
10.6.2 Ettan DIGE Technology 303
10.6.3 DNA Methylation Technology 303
10.7 Disease-Specific Technology 304
10.7.1 Ovarian Cancer: Bio-Rad's SELDI-based ProteinChip 304
10.7.2 Lung Cancer: Labeled Porphyrin Binding 304
10.7.3 C-MAP, A Cervical Cancer Screening System 304
10.7.4 Lung Cancer: Pro-Gastrin-Releasing Peptide (ProGRP) 304
10.7.5 Prostate Cancer: PCA3 304
10.7.6 Bladder Cancer: ImmunoCyt/uCyt+ 307

11. Market Trends and Forecasts 309
11.1 Ultrasensitive Cancer Tests 309
11.2 Mergers and Acquisitions (M&As) of Diagnostic Companies 310
11.3 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) 310
11.4 Genetic Tests of Hereditary Cancer Risk 311
11.5 DNA Measurements 311
11.6 Technical and Practical Issues for Potential New Markers 311
11.7 Genetic Profiling 313
11.8 Ploidy 313
11.9 Advances in Sputum Analysis for Screening and Early Detection of Lung
Cancer 314
11.10 Pharmacogenetic Tests for Cancer 314
11.11 Worldwide Healthcare Spending 315

Appendix 1: Web Links 317
Appendix 2: Cancer Information Resources 320
Appendix 3: Colon Cancer Staging 321
Appendix 4: Reimbursement for Tumor Marker Testing 323
Appendix 5: The Pathology of Prostate Cancer 326
Appendix 6: Government Regulation of Tumor Marker Tests 328
Appendix 7: The Clinical Laboratory Improvement Act (CLIA) 331
Appendix 8: Marketers of Occult Blood Diagnostic Test Kits 334

INDEX OF FIGURES

Figure 1.1: Medicines in Development in Cancer 15
Figure 4.1: Bowel Cancer including Anal Cancer: 2008 Estimates: World
Age-Standardized Incidence Rates per 100,000 Population, World Regions 67
Figure 4.2: Percentage of Adults Aged 50-75 Years Who Reported Being Up-to-Date
with Colorectal Test Screening, by State Behavioral Risk Factor Surveillance
System in the U.S., 2010 71
Figure 4.3: Model of CRC Development 71
Figure 4.4: Progression of CRC Development 72
Figure 4.5: Prostate Cancer (C61): 2008 Estimates: World Age-Standardized
Incidence Rates per 100,000 Population, Males, World Regions 81
Figure 4.6: Prostate Cancer (C61): 2008 Estimates: European Age-Standardized
Incidence Rates per 100,000 Population, Males, EU27 Countries 82
Figure 4.7: Estimates for PCA3 Test Volume in U.S., 2005-2012 105
Figure 4.8: Pancreatic Cancer: 2008 Estimates: World Age-Standardized Incidence
Rates per 100,000 Population, Male and Females, World Regions 115
Figure 4.9: Breast Cancer: 2008 Estimates: World Age-Standardized Incidence
Rates per 100,000 Population, Females, World Regions 120
Figure 4.10: ASCO-CAP Guidelines for HER2 Testing in Breast Cancer: Equivocal
Results with IHC 128
Figure 4.11: ASCO-CAP Guidelines for HER2 Testing in Breast Cancer: Results by
FISH 129
Figure 4.12: Ovarian Cancer: 2008 Estimates: European Age-Standardized Incidence
Rates per 100,000 population, Females, EU27 Countries 132
Figure 4.13: Cervical Cancer: 2008 Estimates: World Age-Standardized Incidence
Rates per 100,000 Population, Females, World Regions 139
Figure 4.14: Lung Cancer: 2008 Estimates: World Age-Standardized Incidence Rates
per 100,000 Population, World Regions 145
Figure 4.15: The BTA stat Test vs. Cytology 162

INDEX OF TABLES

Table 2.1: Organ-Specific Medicines in Development for Cancer 20
Table 2.2: Estimates for the Leading Sites of New Cancer Cases in the U.S. by
Gender, 2013 21
Table 2.3: Estimates for the Leading Sites of Cancer Deaths in the U.S. by
Gender, 2013 21
Table 2.4: Worldwide Number of New Cancer Cases and Deaths by Type of Cancer
(Men) 21
Table 2.5: Worldwide Number of New Cancer Cases and Deaths by Type of Cancer
(Women) 22
Table 2.6: Estimated Age-Standardized Incidence and Mortality Rates Per 100,000
by World Area, 2008 23
Table 2.7: Cancer-Associated Genes 23
Table 2.8: Carcinogens in the Workplace 24
Table 2.9: Private Funding Levels for the Biotechnology Segment, 1995-2012 25
Table 2.10: Herceptin Worldwide Sales, 2000-2017 27
Table 2.11: Classes of Drugs Used to Treat Breast Cancer 28
Table 3.1: Tumor Biomarkers Currently in Common Use 32
Table 3.2: Global IVD Cancer Tumor Marker Testing Market Segments Growth Rates,
2009-2019 33
Table 3.3: Worldwide Market Size in Dollar Volume for Tumor Marker Assays
Product Market,
2009-2019 34
Table 3.4: U.S. Market Size in Dollar Volume for Tumor Marker Assays Product
Market, 2009-2019 34
Table 3.5: Worldwide In Vitro Cancer Tumor Marker Diagnostics Market Size,
2009-2019 35
Table 3.6: U.S. In Vitro Cancer Tumor Marker Diagnostics Market Size, 2009-2019
35
Table 3.7: Japanese In Vitro Cancer Tumor Marker Diagnostics Market Size,
2009-2019 36
Table 3.8: European In Vitro Cancer Tumor Marker Diagnostics Market Size,
2009-2019 36
Table 3.9: Market Share of Major Competitors in U.S. Cancer Tumor Marker
Diagnostics Market 36
Table 3.10: Major Presence in Cancer Tumor Marker Diagnostics Markets 37
Table 3.11: Worldwide PSA Sales, 2009-2019 38
Table 3.12: U.S. PSA Sales, 2009-2019 39
Table 3.13: Serum Markers Used Clinically 39
Table 3.14: Drivers of IHC Growth 44
Table 3.15: Bladder Cancer Testing Efforts in the U.S. and Germany 49
Table 3.16: Worldwide Bladder Cancer Marker Sales, 2009-2019 51
Table 3.17: U.S. Bladder Cancer Marker Sales, 2009-2019 51
Table 3.18: Worldwide NMP22 Sales, 2009-2019 52
Table 3.19: Breast Cancer Products and Product Opportunities, 2011 60
Table 3.20: Products in Various Stages of Development for Cancers Other than
Breast Cancer 62
Table 4.1: CRC Stages 68
Table 4.2: Percentage of Respondents Aged =50 Years who Reported Receiving a
Fecal Occult Blood Test Within One Year, or a Lower Endoscopy* Within Ten Years,
by Age and Sex in the U.S., 2002, 2004,
2006 and 2008 70
Table 4.3: Number of Procedures Based on Patients Aged =50 Years who Reported
Receiving a Fecal Occult Blood Test Within One Year or a Lower Endoscopy* Within
Ten Years, by Age and Sex in the U.S., 2008 70
Table 4.4: Worldwide CEA Sales, 2009-2019 72
Table 4.5: U.S. CEA Sales, 2009-2019 73
Table 4.6: Japan CEA Sales, 2009-2019 73
Table 4.7: Europe CEA Sales, 2009-2019 74
Table 4.8: Rest of the World CEA Sales, 2009-2019 74
Table 4.9: Worldwide PSA Sales, 2009-2019 79
Table 4.10: U.S. PSA Sales, 2009-2019 79
Table 4.11: Japan PSA Sales, 2009-2019 80
Table 4.12: Europe PSA Sales, 2009-2019 80
Table 4.13: Rest of the World PSA Sales, 2009-2019 81
Table 4.14: Population Statistics of Serum Levels of PSA in Men Over 50 Years of
Age 88
Table 4.15: Cell Doubling Time and Time to Reach PSA Level of 1,000 ng/mL 89
Table 4.16: Human tissue Kallikreins as Cancer Markers 93
Table 4.17: New Diagnostic Tests for Prostate Cancer 99
Table 4.18: Gen-Probe Genetic Testing Product Line 106
Table 4.19: Prostate Cancer Molecular Diagnostic Testing Market: Market Drivers
Ranked in Order of
Impact 112
Table 4.20: Prostate Cancer Molecular Diagnostic Testing Market: Market
Restraints Ranked in Order of
Impact 112
Table 4.21: Summary of Strengths, Weaknesses, Opportunities and Threats of the
Prostate Cancer Molecular Diagnostic Market 113
Table 4.22: Worldwide CA 19-9 Sales, 2009-2019 116
Table 4.23: U.S. CA 19-9 Sales, 2009-2019 116
Table 4.24: Japan CA 19-9 Sales, 2009-2019 117
Table 4.25: Europe CA 19-9 Sales, 2009-2019 117
Table 4.26: Rest of the World CA 19-9 Sales, 2009-2019 118
Table 4.27: CA 19-9 Levels in Management of Pancreatic Cancer 118
Table 4.28: Worldwide CA 15-3 Sales, 2009-2019 121
Table 4.29: U.S. CA 15-3 Sales, 2009-2019 122
Table 4.30: Japan CA 15-3 Sales, 2009-2019 122
Table 4.31: Europe CA 15-3 Sales, 2009-2019 123
Table 4.32: Rest of the World CA 15-3 Sales, 2009-2019 123
Table 4.33: TPA Marker Sensitivity 126
Table 4.34: ASCO-CAP Guidelines for HER2 Testing in Breast Cancer: How to
Interpret Test Results 127
Table 4.35: Oncogene Science Biomarker Group Reagents 130
Table 4.36: Worldwide CA-125 Sales, 2009-2019 133
Table 4.37: U.S. CA-125 Sales, 2009-2019 134
Table 4.38: Japan CA-125 Sales, 2009-2019 134
Table 4.39: Europe CA-125 Sales, 2009-2019 135
Table 4.40: Rest of the World CA-125 Sales, 2009-2019 135
Table 4.41: Worldwide HVP Sales, 2009-2019 140
Table 4.42: U.S. HVP Sales, 2009-2019 140
Table 4.43: Japan HVP Sales, 2009-2019 141
Table 4.44: Europe HVP Sales, 2009-2019 141
Table 4.45: Rest of the World HVP Sales, 2009-2019 142
Table 4.46: HCPCS Codes for Screening Pap Tests 143
Table 4.47: HCPCS Codes for Screening Pap Tests 143
Table 4.48: Number of Pap Smears Performed by Country 144
Table 4.49: Lung Cancer Survival Rates 146
Table 4.50: American Cancer Society Lung Cancer Facts 147
Table 4.51: Predictive and Prognostic Rates 152
Table 4.52: Tests Identifying Molecular Markers in Urine 157
Table 4.53: Worldwide NMP22/BTA Sales, 2009-2019 158
Table 4.54: U.S. NMP22/BTA Sales, 2009-2019 158
Table 4.55: Japan NMP22/BTA Sales, 2009-2019 159
Table 4.56: Europe NMP22/BTA Sales, 2009-2019 159
Table 4.57: Rest of the World NMP22/BTA Sales, 2009-2019 160
Table 4.58: Patient Category Applications 160
Table 4.59: Worldwide Alpha-Fetal Protein (AFP) Sales, 2009-2019 165
Table 4.60: U.S. Alpha-Fetal Protein (AFP) Sales, 2009-2019 166
Table 4.61: Japan Alpha-Fetal Protein (AFP) Sales, 2009-2019 166
Table 4.62: Europe Alpha-Fetal Protein (AFP) Sales, 2009-2019 167
Table 4.63: Rest of the World Alpha-Fetal Protein (AFP) Sales, 2009-2019 167
Table 4.64: Key Oncology Diagnostic Tests, Roche, 2013 172
Table 4.65: Potential Uses of Molecular Diagnostics in Cancer Management 179
Table 4.66: Markers Frequently Used to Identify Adult Stem Cells in the
Prostate, Breast and Intestine 185
Table 4.67: MammaPrint: Key Features 191
Table 6.1: Tumor Marker Tests 217
Table 6.2: Tumor Diagnosis Immunoassays 218
Table 6.3: Tumor Diagnosis Radioimmunoassays 218
Table 6.4: PBM Product List 242
Table 7.1: List and Discounted Prices for Abbott Tumor Marker Tests 252
Table 8.1: CPT Codes for Tumor Markers 265
Table 10.1: Categories of Oncogenes 283
Table 10.2: Familial Cancer Syndromes and Tumor Suppressor Genes 286
Table A3.1: TNM Classification 321
Table A7.1: Financial Comparison for Moderate and Waived CLIA Labs 331
Table A8.1: List of Marketers of Occult Blood Diagnostic Test Kits 334

Read the full report:
Cancer Diagnostic Testing World Markets

http://www.reportbuyer.com/pharma_healthcare/diagnostics/cancer_diagnostic_testing_world_markets.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

©2012 PR Newswire. All Rights Reserved.